Monoclonal Antibody News and Research

RSS

Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

YM BioSciences announces results of nimotuzumab Phase II study on DIPG

YM BioSciences Inc. today announced that preliminary results of a Phase II study evaluating the safety and efficacy of nimotuzumab in pediatric patients with recurrent diffuse intrinsic pontine glioma (DIPG) were reported at the 43rd Congress of the International Society of Paediatric Oncology (SIOP) conference being held in Auckland, New Zealand.

31 Oct 2011

Thyroid researcher to receive ATA's John B. Stanbury Pathophysiology Medal

Each year, the American Thyroid Association (ATA) recognizes the outstanding research contributions of one of its members to a greater understanding of thyroid physiology or the pathophysiology of thyroid disease, with its presentation of the John B. Stanbury Pathophysiology Medal at its Annual Meeting.

29 Oct 2011

BZL and ATLAB Pharma partner to develop 177Lu-J591 for metastatic prostate cancer treatment

ATLAB Pharma SAS and BZL Biologics LLC have entered into a sublicense agreement to develop 177Lu-J591 for cancer treatment. It includes exclusive rights to manufacture, develop and commercialize this radiopharmaceutical product worldwide as well as a joint Phase IIB/III clinical validation program.

29 Oct 2011

NCI awards UAB $2.3M brain-tumor SPORE grant

The UAB Comprehensive Cancer Center and the UAB Division of Neurosurgery have been awarded a prestigious SPORE, or Specialized Program of Research Excellence, grant from the National Cancer Institute for $2.3 million over three years to conduct research and develop new therapies to treat brain tumors.

28 Oct 2011

Regeneron announces positive results from sarilumab Phase 2b trial on RA

Regeneron Pharmaceuticals, Inc. today announced that detailed clinical data from the positive Phase 2b portion of the seamless Phase 2/3 MOBILITY trial of sarilumab in rheumatoid arthritis (RA) will be presented at a late-breaking poster session at the upcoming American College of Rheumatology (ACR) Annual Scientific Meeting, which will take place from November 5-9 in Chicago.

28 Oct 2011

Abzyme Therapeutics licenses SUMOpro from LifeSensors

Abzyme Therapeutics, a new biotechnology company dedicated to developing methods to generate human monoclonal antibodies for the treatment of disease, announced today that they have entered into an exclusive agreement with LifeSensors to license their proprietary protein expression platform, SUMOpro™. Enhanced protein expression is key to the evolution and development of antibodies and the LifeSensors

24 Oct 2011

DNA synbodies, a new class of affinity reagents, gets major NIH boost

An ongoing Arizona State University effort to develop a revolutionary class of reagents that holds great promise for the future of medicine has received a major boost with a three-year, $4 million award from the National Institutes of Health.

24 Oct 2011

Abbott, Biogen Idec announce additional results from daclizumab HYP Phase 2b trial for RRMS

Today Biogen Idec and Abbott announced additional results from the SELECT Phase 2b trial, the first of two registrational studies designed to evaluate the investigational compound daclizumab high-yield process in people with relapsing-remitting multiple sclerosis.

22 Oct 2011

Sanofi announces new results from alemtuzumab-Rebif comparative CARE-MS I trial

Sanofi and its subsidiary Genzyme announced today new results from the CARE-MS I trial, the first of two randomized, Phase III clinical trials comparing the investigational drug alemtuzumab to Rebif (high dose subcutaneous interferon beta-1a) in patients with relapsing-remitting multiple sclerosis.

22 Oct 2011

Xencor commences XmAb5871 Phase 1 trial in autoimmune diseases

Xencor, Inc., a company using its proprietary Protein Design Automation (PDA) platform technology to engineer next-generation antibodies, announced today the initiation of a Phase 1 clinical trial of XmAb5871, the company's therapeutic antibody for the treatment of autoimmune diseases.

22 Oct 2011

Genentech announces 96-week results from ocrelizumab Phase II study on RRMS

Genentech, a member of the Roche Group, today announced 96-week results from a Phase II study of ocrelizumab in patients with relapsing-remitting multiple sclerosis (RRMS), the most common clinical form of the disease.

21 Oct 2011

Breakthrough in development of effective therapy against Hendra virus

A team of Federal and university scientists reports a breakthrough in the development of an effective therapy against a deadly virus, Hendra virus. The results of their study, "A Neutralizing Human Monoclonal Antibody Protects African Green Monkeys from Hendra Virus Challenge," will appear in Science Translational Medicine online.

20 Oct 2011

Comprehensive roadmap promises to improve cancer immunotherapy development

The Cancer Immunotherapy Consortium (CIC) of the Cancer Research Institute (CRI) and the Association for Cancer Immunotherapy (CIMT) have issued a joint white paper, published in the October 13 issue of Nature Biotechnology, outlining a comprehensive roadmap that promises to help improve and facilitate the path forward in the development of novel immunotherapies for cancer.

19 Oct 2011

Janssen, BeiGene enter in-licensing agreement for two clinical-stage oncology compounds

BeiGene, Ltd., today announced that it has entered into exclusive in-licensing and co-development agreements with Janssen Pharmaceutica NV and its affiliates for two clinical-stage oncology compounds.

15 Oct 2011

Four companies receive NIAID contracts to develop broad-spectrum therapeutics

Four companies are to develop broad-spectrum therapeutics-antibiotics, antivirals and an antitoxin-to prevent or treat diseases caused by multiple types of bacteria or viruses, under contracts awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

14 Oct 2011

Micromet receives FDA feedback on blinatumomab registration for R/R ALL

Micromet, Inc. today outlined a clinical development plan intended to support U.S. registration of its lead product candidate blinatumomab in patients with B-precursor relapsed/refractory (r/r) acute lymphoblastic leukemia.

14 Oct 2011

Oncobiologics signs two major pharmaceutical agreements

Oncobiologics announced today that it has signed two major agreements. The first is with Parilis Biopharmaceuticals, an early-stage biotech company, and involves worldwide licensing for an undisclosed biotherapeutic product. The second is with a US based large pharmaceutical company to conduct research focused on solving issues related to downstream processing of monoclonal antibodies.

14 Oct 2011

Merrimack begins MM-121 Phase 2 combination trial in HER2-negative breast cancer

Merrimack Pharmaceuticals, Inc. announced today that the first patient has been dosed in a randomized Phase 2 clinical trial of MM-121, a fully human monoclonal antibody that targets ErbB3, combined with paclitaxel in the neoadjuvant setting of HER2-negative breast cancer patients.

12 Oct 2011

Roche's gantenerumab removes amyloid plaques from the brain of patients with AD

Roche today announced the publication of a study demonstrating that its monoclonal antibody gantenerumab removes amyloid plaques from the brain of patients with Alzheimer's disease. The study "Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab" is published today in the October issue of Archives in Neurology.

11 Oct 2011

X-BODY, TRL enter collaboration to identify therapeutic target epitopes

X-BODY, Inc., a developer of monoclonal antibody therapeutics, today announced a partnership with Tanabe Research Laboratories U.S.A., Inc. (TRL). The companies will collaborate to identify therapeutic target epitopes and develop monospecific and/or bispecific antibodies to the identified therapeutic targets.

4 Oct 2011